[HTML][HTML] ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38 …
K Airiau, FX Mahon, M Josselin, M Jeanneteau… - Experimental …, 2012 - Elsevier
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34 (+) CD38 (-) …
K Airiau, FX Mahon, M Josselin… - Experimental …, 2012 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
[PDF][PDF] ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34þ CD38À …
K Airiaua, FX Mahona, M Josselina… - Experimental …, 2012 - academia.edu
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38 …
K Airiau, FX Mahon, M Josselin, M Jeanneteau… - Experimental …, 2012 - infona.pl
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34 (+) CD38 (-) …
K Airiau, FX Mahon, M Josselin… - Experimental …, 2012 - europepmc.org
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
[HTML][HTML] ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38 …
K Airiau, FX Mahon, M Josselin, M Jeanneteau… - Experimental …, 2012 - exphem.org
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38 …
K Airiau, FX Mahon, M Josselin, M Jeanneteau… - Experimental …, 2012 - hal.science
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
[PDF][PDF] ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34þ CD38À …
K Airiau, FX Mahon, M Josselin… - Experimental …, 2012 - academia.edu
Chronic myeloid leukemia (CML) tumorigenicity is driven by the oncogenic BCR-ABL
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …
tyrosine kinase. Specific tyrosine kinase inhibitors (TKI) have been designed and are now …